Compares safety and antiretroviral effect of current standard ART to once daily intergrase inhibitor (INSTI) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed children.

This ongoing two arm, phase 2/3 multi-centre, open label randomized study that started in April 2019 at the Baylor-Uganda COE HIV clinic is sponsored by PENTA Foundation and aims to maintain HIV viral suppression with once daily dolutegravir +darunavir/ritonavir (DTG/DRV/RTV) in children. This dual therapy strategy which combines boosted protease inhibitor (bPI) plus integrase inhibitor (INSTI) could be an excellent choice for switching children that are virally suppressed from NRTIs and NNRTI-based regimens to reduce drug toxicity while maintaining viral suppression with life-long ART. For more details